Author: Deepbio

On May 28th, AI startup ‘Deep Bio’ succeeded in Series A funding from various venture capital companies in Korea. Deep Bio is a medicalAI company that develops cancer diagnostic software products. While the products are still under development, it is expected to accelerate the commercialization.

Deep Bio has closed USD 5.6 Million in its Series A round from domestic venture capital companies. The startup has been recognized as an enterprise worth about USD 14 Million (before investment) in the process of attracting investment.

DTI & Investment, Hyundai Investment, Sejong Venture Partners, Daesung Venture Investment, and MG Investments acquired a total of 296,298 shares of DeepBio’s redeemable convertible preferred stock (RCPS). Some venture capitalists are also considering additional follow-on investments for additional financial support.

DeepBio was founded in October 2015 by Kim Sun-Woo, a computer engineer graduate from KAIST University. The company is a startup specializing in the production of medical software using deep learning, one of the artificial intelligence technologies.

The startup company is conducting clinical trials on its medical devices based on its solutions. It is anticipated that the products will be launched in earnest after completing the clinical procedure. The company plans to actively pursue not only in domestic but also overseas bio markets. Deep Bio is regarded as a representative start-up that provides a combination of information & communication technology (ICT) and bio. In the era of the 4th Industrial Revolution, Deep Bio has gained its reputation from investment companies in the essence that contributes value in domestic and foreign markets.

An industry representative said, “Deep Bio is a promising venture company in the era of the fourth industrial revolution, and if successful, the company will be able to grow and attract attention in overseas markets.” He said.

For more information:
https://www.thebell.co.kr/free/content/ArticleView.asp?key=201802280100056660003574&lcode=00

2018.03.02
TheBell

“Learning amount ↑ · Error ↓” Utilization as a clinical supporting device ..

Artificial Intelligence (AI) has now made its headway into the biotech industry. Google is presenting a new technology revolution where systems such as ‘Alpha Go’ are involved in new drug development, diagnosis, and treatment. However, experts in artificial intelligence do not have it easy to commercializing the technology into the biofield. There are no proven business models in which start-ups and small businesses are struggling to establish and can profit from. In this regard, it is worth noting that Deep Bio, formed in 2015., is a company with real experts in artificial intelligence and IT. Majority of the employees have been developing a model through constant communication and collaboration with medical and bio-professionals. Deep Bio has set early goals to help physicians diagnose prostate cancer more accurately and efficiently.

Taking a look on the process of diagnosing prostate cancer, the first initial step is measuring the prostate-specific antigen (PSA) level based on a blood test. When the PSA level results are abnormal, a prostate biopsy is recommended to examine further for suspicious areas. The prostate tissues collected from the biopsy test are examined under a microscope by a pathologist. Pathologists use the Gleason Scoring system guideline to observe and determine the cancer severity based on the tissue patterns.

Sun Woo Kim, the founder, and CEO of Deep Bio pointed out the limitations of the pathological diagnosis process. “Even when the same physician analyzes the same tissue again in time, the diagnostic concordance rate is about 80%. Also, there is an inter and intra-observer variability between pathologists interpreting the slides, so therefore, AI-diagnostic software developed by Deep Bio can be a solution to this problem. Deep Bio’s AI-diagnostic software is built by digitally scanning the tissues and using these images to train the model. “The software can learn and store myriad sample images in a short period because deep learning has the unlimited capacity to learn,” Kim said.

Kim also mentioned the barriers to examining cancer through artificial intelligence. Due to the variability of tissue staining & slide preparation done by different hospitals, it can cause image variations potentially making it uneasy for AI to analyze images. “To solve this problem, we have developed an algorithm that corrects the new image colors according to the image that is the reference point,” Kim said. The company has confirmed that it has the highest accuracy in reading the images when applying the algorithm developed by Deep Bio.

The company plans to expand its services into the U.S market espousing the shortage of pathologists. There are companies in the U.S. that are developing artificial intelligence in pathology, and one of the notable companies are PathAI, who was founded by Adityco Kosla & Andrew Beck. PathAI is currently collaborating with Philips on breast cancer and other types of diseases.

The Deep Bio founder emphasized that “AI cannot wholly replace pathologists. Instead, it can help them make better decisions to treat patients.” And further said, “So it is important for us to keep improving our technology by finding the best mechanisms and methods and apply it into our model.”

Deep Bio’s vision is to develop a company that can significantly contribute to the bio industry. And Kim further said his goal is to build a company that adds value to society.

For more information:

http://www.biospectator.com/view/news_view.php?varAtcId=4030

2017.09.18
Biospector

Deep Bio, is a start-up company that develops artificial intelligence (AI) to diagnose prostate cancer. There are diagnostic imagining methods such as X-rays and computed tomography (CT) to detect prostate cancer, but Deep Bio uses H&E stained biopsy digital whole slide images for AI to analyze prostate glands. Artificial Intelligence examines prostate glands based on tissue pattern recognition and the shape of the cell to help reduce diagnostic errors. To ensure cancer is present, a biopsy procedure is done to confirm it. For this reason, Deep Bio can help physicians make accurate decisions. “It can be used to observe and predict patients’ prognosis,” said Kim Sun-woo, Deep Bio Founder & CEO (46), and further mentioned, “it will significantly reduce the diagnostic error rate.”

Early this year, Deep Bio has granted a total of 1.9 billion Korean Won seed funding from large investment firms in Korea such as Neo Flux. Kim said, “based on my years of engineering experience, I realized the importance of the engineering ability to create high quality that AI can learn.” Deep Bio develops its own uniquely architectured model that enables AI to learn efficiently. Kim stated that his company predominantly attracted the investors by its exclusive technology.

For more information:
http://news.mk.co.kr/newsRead.php?year=2017&no=542748

 

2017.08.13
MK.매일경제